Immunotherapy in asthma: An updated systematic review

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 54, Issue 10, 1999, Pages 1022-1041

  Abramson, M ^a   Puy, R ^a   Weiner, J ^b  

^a ALFRED HOSPITAL   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

Asthma; Immunotherapy; Meta analysis; Randomized controlled trials

Indexed keywords

HOUSE DUST ALLERGEN; POLLEN ANTIGEN;

ALLERGY; ANAPHYLAXIS; ANTIGEN SPECIFICITY; ASTHMA; BRONCHUS HYPERREACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DANDER; DESENSITIZATION; FATALITY; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MAST CELL; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ASTHMA; EVALUATION STUDIES; HUMANS; IMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIALS;

EID: 0032822158     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1398-9995.1999.00102.x     Document Type: Review

References (205)

1. Wecke B. The future for immunotherapy. Clin Exp Allergy 1991; 21 Suppl 1:86-92.
2. Henry RL, Landau LI, Mellis C, et al. Childhood asthma: application of the international view of management in Australia and New Zealand. J Paediatr Child Health 1990;26:72-74.
3. Bousquet J, Lockey RF, Malling H-J. Allergen immunotherapy - therapeutic vaccines for allergic diseases. Allergy 1998; 53 Suppl 44:4-42.
4. Abramson M, Puy R, Weiner J. Is allergen immunotherapy effective in asthma? A meta-analysis of randomised controlled trials. Am J Respir Crit Care Med 1995;151:969-974.
5. Abramson MJ, Puy RM, Weiner JM. Allergen specific immunotherapy for asthma (Cochrane Review). Cochrane Library, Issue 3 1998. Oxford: Update Software.
6. Kunz R, Oxman AD. The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials. BMJ 1998;317:1185-1190.
7. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clin Trials 1996;17:1-12.
8. Clarke M, Fischer M, Moustgaard R, Riis J. User guide for Review Manager (RevMan). Version 3.1 for Windows. Cochrane Collaboration, 1997.
9. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997;127:820-826.
10. Aas K. Hyposensitization in house dust allergy asthma. A double-blind controlled study with evaluation of the effect on bronchial sensitivity to house dust. Acta Paediatr Scand 1971;60:264-268.
11. Adkinson NF, Eggleston PA, Eney D, et al. A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med 1997;336:324-331.
12. Alvarez Cuesta E, Cuesta Herranz J, Puyana Ruiz J, Cuesta Herranz C, Blanco Quiros A. Monoclonal antibody-standardized cat extract immunotherapy: risk-benefit effects from a double-blind placebo study. J Allergy Clin Immunol 1994;93:556-566.
13. Amaral Marques R, Avila R. Results of a clinical trial with a Darmatophagoides pteronyssinus tyrosine adsorbed vaccine. Allergol Immunopathol (Madr) 1978;6:231-235.
14. Armentia Medina A, Blanco Quiros A, Martin Santos JM, et al. Rush immunotherapy with a standardized Bermuda grass pollen extract. Ann Allergy 1989;63:127-135.
15. Armentia Medina A, Tapias JA, Martin JF, Ventas P, Fernandez A. Immunotherapy with the storage mite Lepidoglyphus destructor. Allergol Immunopathol (Madr) 1995;23:211-223.
16. British Tuberculosis Association. Treatment of house dust allergy. BMJ 1968;3:774-777.
17. British Thoracic Association. A trial of house dust mite extract in bronchial asthma. Br J Dis Chest 1979;73:260-270.
18. Baur X. Hyposensitization in bronchial asthma - still a current therapeutic procedure? Med Klin 1989;84:439-444.
19. Bertelsen A, Andersen JB, Christensen J, Ingermann L, Kristensen T, Østergaard PA. Immunotherapy with dog and eat extracts in children. Allergy 1989;44:330-335.
20. Bousquet J, Guerin B, Dotte A, et al. Comparison between rush immunotherapy with a standardised allergen and an alum adjuved pyridine extracted material in grass pollen allergy. Clin Allergy 1985;15:179-193.
21. Bousquet J, Calvayrac P, Guerin B, et al. Immunotherapy with a standardised Dermatophagoides pteronyssinus extract. I. In vivo and in vitro parameters after a short course of treatment. J Allergy Clin Immunol 1985;76:734-744.
22. Bousquet J, Hejjaoui A, Clauzel AM, et al. Immunotherapy with a standardised Dermatophagoides pteronyssinus extract. II. Predíction of efficacy of immunotherapy J Allergy Clin Immunol 1988;82:971-977.
23. Bousquet J, Maasch HJ, Hejjaoui A, et al. Double blind placebo controlled immunotherapy with mixed grass pollen allergoids. III. Efficacy and safety of unfractionated and high molecular weight preparations in rhinoconjunctivitis and asthma. J Allergy Clin Immunol 1989;84:546-556.
24. Bousquet J, Hejjaoui A, Soussana M, Michel FB. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. IV. Comparison of the safety and efficacy of two dosages of a high-molecular-weight allergoid. J Allergy Clin Immunol 1990;85:490-497.
25. Bruce CA, Norman PS, Rosenthal RR, Lichtenstein LM. The role of ragweed pollen in autumnal asthma. J Allergy Clin Immunol 1977;59:449-459.
26. Buchanan DJ, Hillis A, Williams PN. A double blind controlled trial of Bencard house dust mite (Migen) hyposensitization in Zambian asthmatics. Med J Zambia 1981;15:14-16.
27. Cantani A, Ragno V, Monteleone MA, Lucenti P, Businco L. Enzyme potentiated desensitisation in children with asthma and mite allergy: a double blind study. J Investig Allergol Clin Immunol 1996;6:270-276.
28. Choovoravech P. Effect of immunotherapy in bronchial asthma: treatment with extracts of house dust and mite. J Med Assoc Thai 1974;57:445-449.
29. Creticos PS, Reed CS, Norman PS, et al. Ragweed immunotherapy in adult asthma. N Engl J Med 1996;334:501-506.
30. D'Souza MF, Pepys J, Wells ID, et al. Hyposensitisation with Dermatophagoides pteronyssinus in house dust allergy: a controlled study of clinical and immunological effects. Clin Allergy 1973;3:177-193.
31. Dolz I, Martínez-Cócera C, Bartolomé JM, Cimarra M. A double-blind placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy. Allergy 1996;51:489-500.
32. Dreborg S, Agrell B, Foucard T, et al. A double blind multicentre immunotherapy trial in children using a purified and standardised Cladospotium herbarum preparation. Allergy 1986;41:131-140.
33. Franco C, Barbadori S, Freshwater LL, Kordash TR. A double-blind, placebo controlled study of Alpare mite D. pteronyssinus immunotherapy in asthmatic patients. Allergol Immunopathol (Madr) 1995;23-58-66.
34. Frankland AW, Augustin R. Prophylaxis of summer hay fever and asthma. Lancet 1954;1:1055-1057.
35. Gaddie J, Skinner C, Palmer KNV. Hyposensitisation with house dust mite vaccine in bronchial asthma. BMJ 1976;2:561-562.
36. Haugaard L, Dahl R. Immunotherapy in patients allergic to cat and dog dander. 1. Clinical results. Allergy 1992;47:249-254.
37. Hill DJ, Hosking CS, Shelton MJ, Turner MW. Failure of hyposensitisation in treatment of children with grass-pollen asthma. BMJ 1982;284:306-309.
38. Johnstone DE. Study of the role of antigen dosage in the treatment of pollenosis and pollen asthma. Am J Dis Child 1957;94:1-5.
39. Johnstone DE, Crump L. Value of hyposensitisation therapy for bronchial asthma in children. Pediatrics 1961;27:39-44.
40. Johnstone DE, Dutton A. The value of hyposensitisation therapy for bronchial asthma in children - a 14 year study. Pediatrics 1968;42:793-802.
41. Kohno Y, Minoguchi K, Oda N, et al. Effect of rush immunotherapy on airway inflammation and airway hyperresponsiveness after bronchoprovocation with allergen in asthma. J Allergy Clin Immunol 1998;102:927-934.
42. Kuna P, Alam R, Kuzminska B, Rozniecki J. The effect of preseasonal immunotherapy on the production of histamine-releasing factor (HRF) by mononuclear cells from patients with seasonal asthma: results of a double-blind, placebo-controlled, randomized study. J Allergy Clin Immunol 1989;83:816-824.
43. Machiels JJ, Somville MA, Lebrun PM, Lebecque SJ, Jacquemin MG, Saint Remy JMR. Allergic bronchial asthma due to Dermatophagoides pteronyssinus hypersensitivity can be efficiently treated by inoculation of allergen-antibody complexes. J Clin Invest 1990;85:1024-1035.
44. Machiels JJ, Buche M, Somville MA, Jacquemin MG, Saint-Remy JM. Complexes of grass pollen allergens and specific antibodies reduce allergic symptoms and inhibit the seasonal increase of IgE antibody. Clin Exp Allergy 1990;20:653-660.
45. Machiels JJ, Somville MA, Jacquemin MG, Saint-Remy JMR. Allergen-antibody complexes can efficiently prevent seasonal rhinitis and asthma in grass pollen hypersensitive patients. Allergen-antibody complex immunotherapy. Allergy 1991;46:335-348.
46. Machiels JJ, Lebrun PM, Jacquemin MG, Saint-Remy JM. Significant reduction of nonspecific bronchial reactivity in patients with Dermatophagoides pteronyssinus-sensitive allergic asthma under therapy with allergen-antibody complexes. Am Rev Respir Dis 1993;147:1407-1412.
47. Malling H-J. Diagnosis and immunotherapy of mould allergy. With special reference to Cladosporium herbarum. Dan Med Bull 1990;37:12-22.
48. Malling H-J, Dreborg S, Weeke B. Diagnosis and immunotherapy of mould allergy. V. Clinical efficacy and side effects of immunotherapy with Cladosporium herbarum. Allergy 1986;41:507-519.
49. Malling H-J, Dreborg S, Weeke B. Diagnosis and immunotherapy of mould allergy. VI. IgE-mediated parameters during a one-year placebo-controlled study of immunotherapy with Cladosporium. Allergy 1987;42:305-314.
50. Maunsell K, Wraith DG, Hughes AM. Hyposensitisation in mite asthma. Lancet 1971;1:967-968.
51. Mosbech H, Dreborg S, Frolund L, et al. Hyposensitisation in asthmatics with mPEG modified and unmodified house dust mite extract. I. Clinical effect evaluated by diary cards and a retrospective assessment. Allergy 1989;44:487-498.
52. Mosbech H, Dreborg S, Frolund L, et al. Hyposensitisation in asthmatics with mPEG modified and unmodified house dust mite extract. II. Effect evaluated by challenges with allergen and histamine. Allergy 1989;44:499-509.
53. Mosbech H, Dirkson A, Dreborg S, et al. Hyposensitization in asthmatics with mPEG-modified and unmodified house dust mite extract. IV. Occurrence and prediction of side effects. Allergy 1990;45:142-150.
54. Newton DAG, Maberly DJ, Wilson R. House dust mite hyposensitisation. Br J Dis Chest 1978;72:21-28.
55. Ohman JL, Findlay SR, Leitermann KM. Immunotherapy in cat induced asthma. Double blind trial with evaluation of in vivo and in vitro responses. J Allergy Clin Immunol 1984;74:230-239.
56. Olsen OT, Larsen KR, Jacobsen L, Svendsen UG. A 1-year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults. Allergy 1997;52:853-859.
57. Ortolani C, Pastorello E, Moss RB, et al. Grass pollen immunotherapy: a single year double blind placebo controlled study in patients with grass pollen induced asthma and rhinitis. J Allergy Clin Immunol 1984;73:283-290.
58. Paranos S, Petrovic S, Early effects of rush immunotherapy with Dermatophagoides pteronyssinus in asthmatics. J Investig Allergol Clin Immunol 1997;7:588-595.
59. Pauli G, Bessot JC, Bigot H, et al. Clinical and immunologic evaluation of tyrosine adsorbed Dermatophagoides pteronyssinus extract: a double blind placebo controlled trial. J Allergy Clin Immunol 1984;74:524-535.
60. Pichler CE, Marquardsen A, Sparholt S, et al. Specific immmunotherapy with Dermatophagoides pteronyssinvs and D. farinae results in decreased bronchial hyperreactivity. Allergy 1997;52:274-283.
61. Price JF, Warner JO, Hey EN, Turner MW, Soothill JF. A controlled trial of hyposensitisation with adsorbed tyrosine Dermatophagoides pteronyssinus antigen in childhood asthma: in vivo aspects. Clin Allergy 1984;14:209-219.
62. Reid MJ, Moss RB, Hsu YP, Kwasnicki JM, Commerford TM, Nelson BL. Seasonal asthma in northern California: allergic causes and efficacy of immunotherapy. J Allergy Clin Immunol 1986;78:590-600.
63. Sabbah A, Bonnaud F, Sonneville A, Bonneau JC, Pinon H. Specific immunotherapy with delayed release D. pteronyssinus alpha fraction. A double blind study in asthma. Allerg Immunol (Paris) 1991;23:58-60.
64. Shaikh WA. Immunotherapy vs inhaled budesonide in bronchial asthma: an open, parallel, comparative trial. Clin Exp Allergy 1997;27:1279-1284.
65. Smith AP. Hyposensitisation with Dermatophagoides pteronyssinus antigen: trial in asthma induced by house dust. BMJ 1971;4:204-206.
66. Sundin B, Lilja G, Graff-Lonnevig V, et al. Immunotherapy with partially purified and standardised animal dander extracts. I. Clinical results from a double blind study on patients with animal dander asthma. J Allergy Clin Immunol 1986;77:478-487.
67. Taylor B, Sanders SS, Norman AP. A double blind controlled trial of house mite fortified house dust vaccine in childhood asthma. Clin Allergy 1974;4:35-40.
68. Taylor WW, Ohman JL, Lowell FC. Immunotherapy in cat induced asthma. Double blind trial with evaluation of bronchial responses to cat allergen and histamine. J Allergy Clin Immunol 1978;61:283-287.
69. Torres Costa JC, Plácido JL, Moreira Silva JP, Delgardo L, Vaz M. Effects of immunotherapy on symptoms, PEFR, spirometry, and airway responsiveness in patients with allergic asthma to house-dust mites (D. pteronyssinus) on inhaled steroid therapy. Allergy 1996;51:238-244.
70. Valovirta E, Koivikko A, Vanto T, Viander M, Ingeman L. Immunotherapy in allergy to dog: a double blind clinical study. Ann Allergy 1984,53:85-88.
71. Valovirta E, Viander M, Koivikko A, Vanto T, Ingeman L. Immunotherapy in allergy to dog. Immunologic and clinical findings of a double-blind study. Ann Allergy 1986;57:173-179.
72. van Bever HP, Stevens WJ. Effect of hyposensitisation upon the immediate and late asthmatic reaction and upon histamine reactivity in patients allergic to house dust mite (Dermatophagoides pteronyssinus). Eur Respir J 1992;5:318-322.
73. van Metre TE, Marsh DG, Adkinson NF, et al. Immunotherapy for cat asthma. J Allergy Clin Immunol 1988;82:1055-1068.
74. Varney VA, Edwards J, Tabbah K, et al. Clinical efficacy of specific immunotherapy to cat dander a double blind placebo controlled trial. Clin Exp Allergy 1997;27:860-867.
75. Vooren PH. Double blind desensitization in asthma. Ned Tijdschr Geneesk 1969;113:2127-2128.
76. Warner JO, Price JF, Soothil JF, Hey EN. Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma. Lancet 1978;2:912-915.
77. Adamek-Guzik T, Szczeklik A, Woloszynski J. Multicentre controlled trial of desensitisation treatment of pollen induced hay fever and asthma with pollinex vaccine. Pol Tyg Lek 1979;34:1111-1113.
78. Almagro E, Asensio O, Bartolomé JM, et al. Multicentric study of pharmacovigilance of sublingual immunotherapy in allergic patients. Allergol Immunopathol (Madr) 1995;23:153-159.
79. Andri L, Senna G, Andri G, et al. Local nasal immunotherapy for birch allergic rhinitis with extract in powder form. Clin Exp Allergy 1995;25:1092-1099.
80. Ariano R, Panzani RC, Chiapella M, Augeri G, Falagiani P. Local immunotherapy of seasonal allergic rhinitis in children due to Parietaria officinalis pollen: a preliminary report. Pediatr Asthma Allergy Immunol 1993;7:227-237.
81. Armentia A, Arranz M, Martin JM, et al. Evaluation of immune complexes after immunotherapy with wheat flour in bakers' asthma. Ann Allergy 1992;69:441-444.
82. Astarita C, Scala G, Sproviero S, Franzesc A. Effects of enzyme potentiated desensitisation in the treatment of pollinosis: a double blind placebo controlled trial. J Investig Allergol Clin Immunol 1996;6:248-255.
83. Bessot JC, Delaume G, Meyer PD, Pauli G. Hyposensitization with Dermatophagoides pteronyssinus tyrosine absorbate in bronchial asthma. Allergol Immunopathol (Madr) 1980;8:351-352.
84. Botey J, Eseverri JL, Marin A, et al. Double blind trial of hyposensitization to Dermatophagoides farinae and D. pteronyssinus in asthmatic children. Allerg Immunol (Paris) 1981;13:16-19.
85. Bousquet J, Becker WM, Hejjaoui A, et al. Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple pollen species. II. Efficacy of a double blind placebo controlled specific immunotherapy with standardized extracts. J Allergy Clin Immunol 1991;88:43-53.
86. Bruun E. Control examination of the specificity of specific desensitisation in asthma. Acta Allergol 1949;2:122-128.
87. Choovoravech P. Effect of immunotherapy: treatment with mite and other acroallergens in Thai allergic patients. J Med Assoc Thai 1980;63:506-511.
88. Choovoravech P, Yongpanich Y, Choovoravech N. Effect of immunotherapy in bronchial asthma: treatment with mite extract adsorbed on tyrosine. Curr Med Res Opin 1976;4:330-339.
89. Chu JC, Wun TH, Chen XJ. Treatment of asthmatic patients sensitive to mites (Dermatophagoides farinae); a four year study of immunotherapy with an extract of Dermatophagoides farinae. Ann Allergy 1981;47:107-109.
90. Clavel R, Bousquet J, André C. Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis. Allergy 1998;53:493-498.
91. Cleveland CH, Metzger WJ. Immunotherapy with pollens and fungi. Immunol Allergy Clin North Am 1992;12:39-52.
92. Cooper PJ, Derbyshire J, Nunn AJ, Warner JO. A controlled trial of oral hyposensitization in pollen asthma and rhinitis in children. Clin Allergy 1984;14:541-550.
93. Corbetta L, Pesiri P, Ferro G, Mander A. Improvement of fog and exercise-induced bronchoconstriction after local and subcutancous immunotherapy in mite asthma. Allergol Immunopathol (Madr) 1992;20:61-66.
94. Corrado OJ, Pastorello E, Ollier S, et al. A double-blind study of hyposensitization with an alginate conjugated extract of D. pteronyssinus (Conjuvac (R)) in patients with perennial rhinitis. I. Clinical aspects. Allergy 1989;44:108-115.
95. Crimi E, Voltolini S, Troise C, et al. Local immunotherapy with Dermatophagoides extract in asthma. J Allergy Clin Immunol 1991;87:721-728.
96. D'Amato G, Kordash TR, Liccardi G, et al. Immunotherapy with Alpare in patients with respiratory allergy to Parietaria pollen: a two year double blind placebo controlled study. Clin Exp Allergy 1995;25:149-158.
97. Des Roches A, Paradis L, Menardo J-L, Bouges S, Daures J-P, Bousquet J. Immunotherapy with a standardised Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitisation in children. J Allergy Clin Immunol 1997;99:450-453.
98. Echechipia S, Tabar AI, Lobera T, et al. Immunotherapy with a standardised Dermatophagoides pteronyssinus glutaraldehyde modified extract against an unmodified extract: a comparative study of efficacy, tolerance and in viva and in vitro modification of parameters. J Investig Allergol Clin Immunol 1995;5:325-332.
99. Engström J, Kracpelien S. Specific desensitisation in bronchial asthma in childhood. Acta Paediatr 1957;46:81-89.
100. Eriksson NE, Ahlstedt S, Löwhagen O. Immunotherapy in spring-time hay fever. A clinical and immunological study comparing two different treatment extract compositions. Allergy 1979;34:233-247.
101. Fanti A, Coccoli M, Pompili T, et al. Randomized double-blind trial of a combination of cromoglycate disodium administration and specific desensitization treatment in adults with perennial extrinsic asthma and nonspecific bronchial hyperreactivity. Lotta Contro la Tuberculosi e le Malattie Polmonari Sociali 1988;58:658-663.
102. Feliziani V, Lattuada G, Parmiani S, DallAglio PP. Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study. Allergol Immunopathol (Madr) 1995;23:224-230.
103. Ferreira N, Trindade JC. Specific immunotherapy 3 years follow-up in asthmatic children. Allergol Immunopathol (Madr) 1993;21:185-192.
104. Formgren H, Lanner A, Lindholm N, Löwhagen O, Dreborg S. Effects of immunotherapy on specific and nonspecific sensitivity of the airways. J Allergy Clin Immunol 1984;73:140.
105. Garcia AN, Paris MB, Carballada F. Immunotherapy in infantile asthma. Pediatr Integral 1997;2:397-404.
106. Giovane AL, Bardare M, Passalacqua G, et al. A three-year double-blind placebo-controlled study with specific oral immunotherapy to Dermatophagoides: evidence of safety and efficacy in paediatric patients. Clin Exp Allergy 1994;24:53-59.
107. Goldstein GL, Chai H. Efficacy of rush immunotherapy in decreasing bronchial sensitivity to inhaled antigens in perennial childhood asthma. Ann Allergy 1981;47:333-337.
108. Goor W, Wuthrich B. Specific therapy of pollinosis. Results of desensitization with two different semi-depot allergen extracts (Allpyral and Suspal). Schweiz Med Wochenschr 1971;101:1217-1221.
109. Gordon VH, Caplinger KJ, Meade JH, Thompson C. Correlation of type specific fluorescent antibodies to ragweed with symptomatology, double-blind study. Ann Allergy 1972;30:507-517.
110. Gozalo F, Martin S, Rico P, Alvarez E, Cortes C. Clinical efficacy and tolerance of two year Lolium perenne sublingual immunotherapy. Allergol Immunopathol (Madr) 1997;25:219-227.
111. Grammer LC, Zeiss CR, Suszko IM, et al. A double-blind, placebo-controlled trial of polymerized whole ragweed for immunotherapy of ragweed allergy. J Allergy Clin Immunol 1982;69:494-499.
112. Grammer LC, Shaughnessy MA, Suszku IM, et al. A double-blind histamine placebo-controlled trial of polymerized whole grass for immunotherapy of grass allergy. J Allergy Clin Immunol 1983;72:448-453.
113. Haahtela T, Wihl JÅ, Munch E, et al. Hyposensitization in hay fever with grass pollen extracts: a three-year study comparing a dialysed alum adsorbed extract with Allpyral(R). Ann Allergy 1984;52:355-362.
114. Haugaard L, Dahl R, Jacobsen L. A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol 1993;91:709-722.
115. Hedlin G, Heilborn H, Lilja G, et al. Long term follow-up of patients treated with a three year course of cat or dog immunotherapy. J Allergy Clin Immunol 1995;96:879-885.
116. Henocq E, Garcelon M, Berrens L. Photo-inactivated allergens. II. Clinical experience with house dust allergen in pulmonary function tests and in immunotherapy. Clin Allergy 1973,3:461-469.
117. Hirsch SR, Kalbfleisch JH, Cohen SH. Comparison of Rinkel injection therapy with standard immunotherapy. J Allergy Clin Immunol 1982;70:183-190.
118. Horst M, Hejjaoui A, Horst V, Michel FB, Bousquet J. Double blind placebo controlled rush immunotherapy with a standardised Alternaria extract. J Allergy Clin Immunol 1990;85:460-472.
119. Jacobsen L, Dreborg S, Moller C, et al. Immunotherapy as preventive allergy treatment. J Allergy Clin Immunol 1996;97:232.
120. Jarisch R, Sandor I, Gotz M, Krummer F. Immunotherapy of allergic disease: studies on 460 patients. Hautarzt 1979;30:365-370.
121. Kalla M, Rozniecki J, Polanska Z, Swatko A. Evaluation of the effectiveness of desensitisation in bronchial asthma caused by house dust mites or grass pollen in the light of clinical results and the histamine and polymyxin inhalation test. Pol Tyg Lek 1979;34:865-868.
122. Kang BC, Johnson J, Morgan C, Chang JL. The role of immunotherapy in cockroach asthma. J Asthma 1988;25:205-218.
123. Kozhemyaka AI, Solodun AK. Effectiveness of the specific hyposensitization of children with allergoses using a peroral vaccine from house dust. Pediatr Akusherstvo Ginekologiia 1979;3:5-7.
124. Laetsch C, Wüthrich B. Towards the oral desensitization of inhalational allergies in childhood: treatment-results. Schweiz Med Wochenscht 1973;103:342-347.
125. Leng X, Fu YX, Ye ST, Duan SQ. A double-blind trial of oral immunotherapy for Artemisia pollen asthma with evaluation of bronchial response to the pollen allergen and scrum-specific IgE antibody. Ann Allergy 1990;64:27-31.
126. Levin SJ. Hyposensitising (immunising) injections in hay fever and asthma. Pediatr Clin North Am 1959;6:698-708.
127. Lichtenstein LM, Norman PS, Winkenwerder WL. A single year of immunotherapy for ragweed hay fever: immunologic and clinical studies. Ann Intern Med 1971;75:663.
128. Lilja G, Sundin B, Graff Lonnevig V, et al. Immunotherapy with cat- and dog-dander extracts. IV. Effects of 2 years of treatment. J Allergy Clin Immunol 1989;83:37-44.
129. Lu F-M, Chou C-C, Chiang B-L, Hsich K-H. Immunologic changes during immunotherapy in asthmatic children: increased IL-13 and allergen-specific IgG4 antibody levels. Ann Allergy 1998;80:419-423.
130. Mallet A, Lluch M, Valero AL, Casanovas M. Clinical and immunological effects of immunotherapy with glutaraldehyde modified house dust mite extract. Allergol Immunopathol (Madr) 1994;22:226-232.
131. Martorell Aragones A, Vila Martinez R, Colomer Sala J. Bronchial asthma. Clinical evolution with hyposensitization. Anales Espanoles Pediatr 1980;13:87-100.
132. Maruo H, Hashimoto K, Shimoda K, et al. Long-term follow up studies of bronchial asthma in children. II. Prognosís and complications, treatment and allergic evaluations. Arerugi 1990;39:662-669.
133. Matoga S, Scislicki A, Haluszka J, Kurzawa R. Results of immunotherapy with HDM (Bencard) in children with bronchial asthma. Pediatr Polska 1989;64:167-172.
134. Matsuoka H, Atsuta Y, Matsubara H, et al. Study of specific IgE and IgG4 antibodies to mite antigen in asthmatic children during immunotherapy. Allergol Int 1998;47:123-128.
135. McAllen MK, Heaf PJD, McInroy P. Depot grass pollen injections in asthma: effect of repeated treatment on clinical response and measured bronchial sensitivity, BMJ 1967;1:22-25.
136. Metzger WJ, Donnelly A, Richerson HB. Modification of late asthmatic responses during immunotherapy for Alternaria induced asthma. J Allergy Clin Immunol 1983;71:119.
137. Miguel Lozano R, Guerra Pasadas F, Arenas Vacas A, Daza Munoz JC, Torres Murillo P, Sanchez Guijo P. Monitoring of various types of immunotherapy with gramineal pollens. I. Variation of clinical and biochemical parameters. Allergol Immunopathol (Madr) 1992;20:230-234.
138. Mischler TW, O'Brien WM, Rugloski RJ, et al. A multiclinic trial with glutaraldehyde-modified tyrosine-adsorbed ragweed pollen immunotherapy (pollinex(R)). Curr Ther Res 1989;29:745-756.
139. Moller C, Dreborg S, Lanner A, Björkstén B. Oral immunotherapy of children with rhinoconjunctivitis due to birch pollen allergy. A double blind study. Allergy 1986;41:271-279.
140. Mosbeeh H. Who will benefit from hyposensitisation? Allergy 1990;45:209-212.
141. Mosbech H, Dreborg S, Frolund L, et al. Immunotherapy with mPEG modified and unmodified D. pteronyssinus extract. Clinical results in a one year double-blind study. Ann Allergy 1985;55:389.
142. Moscato C, Rossi G, Dellabianca A, Pisati A, Vinci G, Riale C. Local immunotherapy by inhalation of a powder extract in asthma due to house dust mite Dermatophagoides pteronyssinus: a double-blind comparison with parenteral immunotherapy. J Investig Allergol Clin Immunol 1991;1:383-394.
143. Moshkevich VS. Local immunotherapy for chronic respiratory allergic pathology with allergen acrosols. II. Treatment of bronchial asthma. Allergol Immunopathol (Madr) 1985;13:317-321.
144. Movérare R, Rak S, Elfman L. Allergen-specific increase in interleukin (IL)-4 and IL-5 secretion from peripheral blood mononuclear cells during birch-pollen immunotherapy. Allergy 1998;53:275-281.
145. Munoz Lejarazu D, Bernaola G, Fernandez E, et al. Seasonal versus perennial immunotherapy: evaluation after three years of treatment. J Investig Allergol Clin Immunol 1993;3:210-216.
146. Munoz-Lopez F. Immunotherapy - methods of treatment and results in children. Allergol Immunopathol (Madr) 1981;(Suppl 9):171-173.
147. Munoz-Lopez F, Martin Mateos A, Moreira A, Martinez Marin F. Topical nasal immunotherapy with Dermatophagoides pteronyssinus extract. Allergol Immunopathol (Madr) 1994;22:132-134.
148. Munro-Ashman D, Frankland AW. Treatment of allergy to house dust with pyridine-extracted alum-precipitated extracts of the house dust mite. Ann Allergy 1976;36:95-98.
149. Murray AB, Ferguson AC, Morrison BJ. Non-allergic bronchial hyperreactivity in asthmatic children decreases with age and increases with mite immunotherapy. Ann Allergy 1985;54:541-544
150. Nagata M, Tabe K, Yamamoto H, et al. The analysis of factors contributing to the safety and efficacy of rush immunotherapy in bronchial asthma. Arerugi 1993;42:628-634.
151. Nagata M, Yamamoto H, Tabe K, et al. Effect of rush immunotherapy in house-dust-mite (HDM)-sensitive adult bronchial asthma: changes in in vivo and in vitro responses to HDM. Int Med 1993;32:702-709.
152. Nagata M, Tabe K, Choo JH, Sakamoto Y, Matsuo H. Effect of immunotherapy on the production of cosinophil adhesion-inducing activity from mononuclear cells in house-dust-mite-sensitive bronchial asthma. Int Arch Allergy Immunol 1998; 117 Suppl 1:20-23.
153. Norman PS, Lichtenstein LM. The clinical and immunologic specificity of immunotherapy. J Allergy Clin Immunol 1978;61:370-377.
154. Novembre E, Marano E, Bernardini R, Caria M, Dini L, Vierucci A. Sublingual immunotherapy in the treatment of allergic asthma in children: a controlled study. Riv Ital Pediatr 1991;17:75-78.
155. Oda N, Yamashita N, Minoguchi K, et al. Long-term analysis of allergen-specific T cell clones from patients with asthma treated with allergen rush immunotherapy. Cell Immunol 1998;190:43-50.
156. Oppenheimer J, Areson JG, Nelson HS. Safety and efficacy of oral immunotherapy with standardized cat extract. J Allergy Clin Immunol 1994;93:61-67.
157. Østerballe O. Immunotherapy with grass pollen major allergens. Allergy 1982;37:379-388.
158. Passalacqua G, Albano M, Fregonese L, et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinaconjunctivitis. Lancet 1988;351:619-632.
159. Paul K, Klettke U, Wahn U. The combined influence of immunotherapy and mite allergen reduction on bronchial hyperresponsiveness in mite-sensitive asthmatic children. Eur J Pediatr 1998;157:109-113.
160. Pence HL, Mitchell DQ, Greely RL, Updegraff BR, Selfridge HA. Immunotherapy for mountain cedar pollinosis: a double blind controlled study. J Allergy Clin Immunol 1976;58:39-50.
161. Petersen BN, Janniche H, Munch EP, et al. Immunotherapy with partially purified and standardized tree pollen extracts. J. Clinical results from a three-year double-blind study of patients treated with pollen extracts either of birch or combinations of alder, birch and hazel. Allergy 1988;43:353-362.
162. Quirino T, Iemoli E, Siciliani B, Parmiani S, Milazzo F. Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study. Clin Exp Allergy 1996;26:1253-1261.
163. Rak S, Löwhagen O, Venge P. The effect of immunotherapy on bronchial hyperresponsiveness and eosinophilic cationic protein in pollen allergic patients. J Allergy Clin Immunol 1988;82:470-480.
164. Rak S, Häkanson L, Venge P. Immunotherapy abrogates the generation of eosinophil and neutrophil chemotactic activity during pollen season. J Allergy Clin Immunol 1990;86:706-713.
165. Rak S, Ahlstedt S, Björkstén B, Fabbri L, Dahl R. Effects of immunotherapy on the inflammation in pollen asthma. Allergy 1993;48 Suppl 17:125-128.
166. Rak S, Hallden G, Sorenson S, Margari V, Scheynius A. The effect of immunotherapy on T-cell subsets in peripheral blood and bronchoalvcolar lavage fluid in pollen-allergic patients. Allergy 1993;48:460-465.
167. Rebien W, Wahn U, Puttonen E, Maasch HJ. Comparative study on the immunological and clinical efficacy of oral and subcutaneous hyposensitization. Allergologie 1980;3:101-106.
168. Reilly DT, Taylor MA, Camphell J, et al. Is homoeopathy a placebo response? A controlled trial of homoeopathic immunotherapy (HIT) in atopic asthma. Complementary Ther Med 1993;1:24-25.
169. Reinert M, Biro G. Hyposensitization with tyrosine-allergoids. Prax Klin Pneumol 1981;35:71-75.
170. Reinert M, Reinert U. Oral hyposensitization with pollen solutions and placebos. Prax Klin Pneumol 1983;37:228-231.
171. Rocha EM. Effect of 2 therapeutic protocols in minor forms of respiratory allergy. Allerg Immunol (Paris) 1986;18:29-41.
172. Rohatgi N, Dunn K, Chai H. Cat or dog induced immediate and late asthmatic responses before and after immunotherapy. J Allergy Clin Immunol 1988;82:389.
173. Rose G, Arlian L, Bernstein D, et al. Evaluation of household dust mite exposure and levels of specific IgE and IgG antibodies in asthmatic patients enrolled in a trial of immunotherapy. J Allergy Clin Immunol 1996;97:1071-1078.
174. Sadan N, Rhyne MB, Mellits ED, et al. Immunotherapy of pollinosis in children: investigation of the immunologic basis of clinical improvement. N Engl J Med 1969;280:623-627.
175. Sanchez Palacios A, Schamann Medina F, Lamas Rua-Figucroa A, Bosch Millares C, Ramos Santos S, Garcia Marrero JA. Comparative clinical-immunological study of oral and subcutancous immunotherapy in children with extrinsic bronchial asthma. Allergol Immunopathol (Madr) 1989;17:323-329.
176. Sanders S. The treatment of seasonal hay fever and asthma in children. A controlled trial of pre-seasonal depot pollen therapy. Practitioner 1966;196:811-815.
177. Saraclar Y, Sekerel RE, Kalayci O, Adalioglu G, Tuncer A. The effect of house dust mite specific immunotherapy on cysteinyl leukotriene production by blood leukocytes in subjects with perennial allergic rhinitis and asthma. J Investig Allergol Clin Immunol 1998;8:98-104.
178. Shen H. The mechanisms and clinical evaluation of allergen specific immunotherapy in patients with asthma. Respirology 1998;3(Suppl):A69.
179. Simons FER, Imada M, Li Y, Watson WTA, HayGlass KT. Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects. Int Immunol 1996;8:1937-1945.
180. Swineford O, Cumbia JW, Berger KW, Lucas DC. Treatment of pollen hay fever and asthma with aerosols of pollen extracts. J Allergy 1955;26:305-319.
181. Sychlowy A, Lukas A, Nowak W, Maruszewski W. Treatment of asthma caused by house dust mites with a combination of Intal and vaccine adsorbed on tyrosine. Pediatr Pol 1979;54:1295-1298.
182. Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol Immunopathol (Madr) 1990;18:277-284.
183. Tari MG, Mancino M, Monti G. Immunotherapy by inhalation of allergen in powder in house dust allergic asthma - a double-blind study. J Investig Allergol Clin Immunol 1992;2:59-67.
184. Taskapan O, Sener O, Ozangue N. Effect of single allergen immunotherapy on early skin reactivity, symptom scores and total IgE levels in grass pollen allergies. Deri Hastaliklari Ve Frengi Arsivi 1998;32:164-170.
185. Taub SJ. Ragweed hay fever and asthma. Illinois Med J 1969;135:706-707.
186. Taudorf E, Weeke B. Orally administered grass pollen. Allergy 1983;38:561-564.
187. Taudorf E, Laursen LC, Djurup R, et al. Oral administration of grass pollen to hay fever patients. All efficacy study in oral hyposensitization. Allergy 1985;40:321-335.
188. Taudorf E, Laursen LC, Lanner A, et al. Oral immunotherapy in birch pollen hay fever. J Allergy Clin Immunol 1987;80:153-161.
189. Tuchinda M, Chai H. Effect of immunotherapy in chronic asthmatic children. J Allergy Clin Immunol 1973;51:131-138.
190. Turner MW, Yalcin I, Soothill JF, et al. In vitro investigations in asthmatic children undergoing hyposensitization with tyrosine-adsorbed Dermatophagoides pteronyssinus antigen. Clin Allergy 1984;14:221-231.
191. Urbanek R, Gehl R. Efficacy of oral hyposensitization treatment in house dust mite allergy. Monatsschr Kinderheilkd 1982;130:150-152.
192. Valovirta E. Capacity of specific immunotherapy in prevention of allergic asthma in children: the preventive allergy treatment study (PAT). J Investig Allergol Clin Immunol 1997;7:369-370.
193. van Bever JP, Bosmans J, De Clerck LS, Stevens WJ. Modification of the late asthmatic reaction by hyposensitisation in asthmatic children allergic to house dust mite (Dermatophagoides pteronyssinus) or grass pollen. Allergy 1988;43:378-385.
194. van Bever HP, Stevens WJ. Suppression of the late asthmatic reaction by hyposensitization in asthmatic children allergic to house dust mite (Dermatophagoides pteronyssinus). Clin Exp Allergy 1989;19:399-404.
195. van Bever HP, Stevens WJ. Evolution of the late asthmatic reaction during immunotherapy and after stopping immunotherapy. J Allergy Clin Immunol 1990;86:141-146.
196. van Bever HP, Vereecke IF, Bridts CH, De Clerck LS, Stevens WJ. Comparison between the in vitro cytokine production of munonuclear cells of young asthmatics with and without immunotherapy (IT). Clin Exp Allergy 1998;28:943-949.
197. Vourdas D, Syrigou E, Potamianou P, et al. Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy 1998;53:662-672.
198. Wahn U, Siraganian RP. Efficacy and specificity of immunotherapy with laboratory animal allergen extracts. J Allergy Clin Immunol 1980;65:413-421.
199. Wahn U, Schweter C, Lind P, Löwenstein H, Prospective study on immunologic changes induced by two different Dermatophagoides pteronyssinus extracts prepared from whole mite culture and mite bodies. J Allergy Clin Immunol 1988;82:360-370.
200. Weyer A, Donat N, L'Heritier C, et al. Grass pollen hyposensitization versus placebo therapy. Allergy 1981;36:309.
201. Wüthrich B, Hafner G, Pollinosis. II. Specific hyposensitisation: indications and results of treatment. A study with the allergen preparation Stallergènes-Depot in the pollen seasons of 1976, 1977 and 1978. Schweiz Med Wochenschr 1980;110:281-290.
202. CONSORT Group. Improving the quality of reporting of randomised controlled trials: the CONSORT statement. JAMA 1996;276:637-639.
203. Weiner J, Abramson M, Puy R, Wilson J. Ragweed immunotherapy in adult asthma [Letter]. N Engl J Med 1996;335:203.
204. Lockey RF. Adverse reactions associated with skin testing and immunotherapy. Allergy Proc 1995;16:293-296.
205. Specific allergen immunotherapy for asthma: a position paper of the Thoracic Society of Australia and New Zealand and the Australasian Society of Clinical Immunology and Allergy. Med J Aust 1997;167:540-544.